Skip to Main content Skip to Navigation
Journal articles

Emerging cardiovascular indications of mineralocorticoid receptor antagonists

Abstract : Mineralocorticoid receptor (MR) antagonism is a well-established treatment modality for patients with hypertension, heart failure, and left ventricular systolic dysfunction (LVSD) post-myocardial infarction (MI). There are emerging data showing potential benefits of MR antagonists in other cardiovascular conditions. Studies have shown association between MR activation and the development of myocardial fibrosis, coronary artery disease, metabolic syndrome, and cerebrovascular diseases. This review examines the preclinical and clinical data of MR antagonists for novel indications including heart failure with preserved ejection fraction (HFPEF), pulmonary arterial hypertension (PAH), arrhythmia, sudden cardiac death, valvular heart disease, metabolic syndrome, renal disease, and stroke. MR antagonists are not licensed for these conditions yet; however, emerging data suggest that indication for MR antagonists are likely to broaden; further studies are warranted.
Complete list of metadata
Contributor : Dcac Ul Connect in order to contact the contributor
Submitted on : Tuesday, March 27, 2018 - 5:27:53 PM
Last modification on : Saturday, December 5, 2020 - 2:08:02 PM




Yasir Parviz, Javaid Iqbal, Bertram Pitt, David Adlam, Abdallah Al-Mohammad, et al.. Emerging cardiovascular indications of mineralocorticoid receptor antagonists. Trends in Endocrinology and Metabolism = Trends in Endocrinology & Metabolism , Elsevier, 2015, 26 (4), pp.201 - 211. ⟨10.1016/j.tem.2015.01.007⟩. ⟨hal-01744918⟩



Record views